iBio, Inc.
IBIONasdaqCIK 1420720HealthcareFiscal year ends Jun 30
Latest reported revenue, Q4 FY2026$0Revenue, Q4 FY2026, three months to 2026-06-30$0. XBRL concept
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-28, accession 0001420720-26-000020. Derived: 12-month figure less the 9-month figure.Report this figureThree months to Jun 30, 2026, from the 10-K filed Aug 28, 2026.Latest quarter: Q4 FY2026
Three months to Jun 30, 2026, against the same quarter a year earlier.
- Revenue$0Revenue, Q4 FY2026, three months to 2026-06-30$0. XBRL concept
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-28, accession 0001420720-26-000020. Derived: 12-month figure less the 9-month figure.Report this figureSign changed from a year earlier - Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
- Operating marginnot reported (Revenue of zero not reported)No year-earlier figure to compare
- Net marginnot reported (Revenue of zero not reported)No year-earlier figure to compare
- Diluted EPSnot reported (Diluted EPS not reported)No year-earlier figure to compare
- Free cash flow−$6.2mFree cash flow, Q4 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$6.2m. XBRL concept
us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-08-28, accession 0001420720-26-000020. Derived: 12-month figure less the 9-month figure.Capital expenditure: $19.0k. XBRL conceptus-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-08-28, accession 0001420720-26-000020. Derived: 12-month figure less the 9-month figure.Report this figure−35.3% on a year earlier
Last eight quarters
Full statements| Line item | Unit | Q1 FY20252024-09-30 | Q2 FY20252024-12-31 | Q3 FY20252025-03-31 | Q4 FY20252025-06-30 | Q1 FY20262025-09-30 | Q2 FY20262025-12-31 | Q3 FY20262026-03-31 | Q4 FY20262026-06-30 | Shape over the periods |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $k | 0.0Revenue, Q1 FY2025, three months to 2024-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q/A filed 2025-11-17, accession 0001420720-25-000043.Report this figure | 200Revenue, Q2 FY2025, three months to 2024-12-31$200.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-10, accession 0001420720-26-000004.Report this figure | 0.0Revenue, Q3 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-02, accession 0001420720-25-000025.Report this figure | 200Revenue, Q4 FY2025, three months to 2025-06-30$200.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-28, accession 0001420720-26-000020. Derived: 12-month figure less the 9-month figure.Report this figure | 100Revenue, Q1 FY2026, three months to 2025-09-30$100.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q/A filed 2025-11-17, accession 0001420720-25-000043.Report this figure | 0.0Revenue, Q2 FY2026, three months to 2025-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-10, accession 0001420720-26-000004.Report this figure | 0.0Revenue, Q3 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001104659-26-059416. Derived: 9-month figure less the 6-month figure.Report this figure | 0.0Revenue, Q4 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-28, accession 0001420720-26-000020. Derived: 12-month figure less the 9-month figure.Report this figure | |
| Gross margin | % | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | |
| Operating margin | % | not reported (Revenue of zero not reported) | (2209.5%)Operating margin, Q2 FY2025, three months to 2024-12-31. operating income / revenueOperating income: −$4.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-02-10, accession 0001420720-26-000004.Revenue: $200.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-10, accession 0001420720-26-000004.Report this figure | not reported (Revenue of zero not reported) | (2599.0%)Operating margin, Q4 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$5.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-08-28, accession 0001420720-26-000020. Derived: 12-month figure less the 9-month figure.Revenue: $200.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-28, accession 0001420720-26-000020. Derived: 12-month figure less the 9-month figure.Report this figure | (5951.0%)Operating margin, Q1 FY2026, three months to 2025-09-30. operating income / revenueOperating income: −$6.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q/A filed 2025-11-17, accession 0001420720-25-000043.Revenue: $100.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q/A filed 2025-11-17, accession 0001420720-25-000043.Report this figure | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | |
| Net margin | % | not reported (Revenue of zero not reported) | (2182.0%)Net margin, Q2 FY2025, three months to 2024-12-31. net income / revenueNet income: −$4.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-12, accession 0001104659-26-059416.Revenue: $200.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-10, accession 0001420720-26-000004.Report this figure | not reported (Revenue of zero not reported) | (2581.5%)Net margin, Q4 FY2025, three months to 2025-06-30. net income / revenueNet income: −$5.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-08-28, accession 0001420720-26-000020. Derived: 12-month figure less the 9-month figure.Revenue: $200.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-28, accession 0001420720-26-000020. Derived: 12-month figure less the 9-month figure.Report this figure | (5720.0%)Net margin, Q1 FY2026, three months to 2025-09-30. net income / revenueNet income: −$5.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-12, accession 0001104659-26-059416.Revenue: $100.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q/A filed 2025-11-17, accession 0001420720-25-000043.Report this figure | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | |
| Diluted EPS | $ per share | (0.46)Diluted EPS, Q1 FY2025, three months to 2024-09-30−$0.46 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q/A filed 2025-11-17, accession 0001420720-25-000043.Report this figure | (0.48)Diluted EPS, Q2 FY2025, three months to 2024-12-31−$0.48 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-10, accession 0001420720-26-000004.Report this figure | (0.49)Diluted EPS, Q3 FY2025, three months to 2025-03-31−$0.49 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001104659-26-059416.Report this figure | not reported (Diluted EPS not reported) | (0.11)Diluted EPS, Q1 FY2026, three months to 2025-09-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q/A filed 2025-11-17, accession 0001420720-25-000043.Report this figure | (0.09)Diluted EPS, Q2 FY2026, three months to 2025-12-31−$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-10, accession 0001420720-26-000004.Report this figure | (0.06)Diluted EPS, Q3 FY2026, three months to 2026-03-31−$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001104659-26-059416.Report this figure | not reported (Diluted EPS not reported) | |
| Free cash flow | $k | (3,715)Free cash flow, Q1 FY2025, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$3.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q/A filed 2025-11-17, accession 0001420720-25-000043.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q/A filed 2025-11-17, accession 0001420720-25-000043.Report this figure | (3,870)Free cash flow, Q2 FY2025, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$3.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-02-10, accession 0001420720-26-000004. Derived: 6-month figure less the 3-month figure.Capital expenditure: $1.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-02-10, accession 0001420720-26-000004. Derived: 6-month figure less the 3-month figure.Report this figure | (3,119)Free cash flow, Q3 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$3.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001104659-26-059416. Derived: 9-month figure less the 6-month figure.Capital expenditure: $14.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-12, accession 0001104659-26-059416. Derived: 9-month figure less the 6-month figure.Report this figure | (4,616)Free cash flow, Q4 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$4.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-08-28, accession 0001420720-26-000020. Derived: 12-month figure less the 9-month figure.Capital expenditure: $1.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-08-28, accession 0001420720-26-000020. Derived: 12-month figure less the 9-month figure.Report this figure | (5,697)Free cash flow, Q1 FY2026, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$5.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q/A filed 2025-11-17, accession 0001420720-25-000043.Capital expenditure: $32.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q/A filed 2025-11-17, accession 0001420720-25-000043.Report this figure | (5,757)Free cash flow, Q2 FY2026, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$5.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-02-10, accession 0001420720-26-000004. Derived: 6-month figure less the 3-month figure.Capital expenditure: $516.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-02-10, accession 0001420720-26-000004. Derived: 6-month figure less the 3-month figure.Report this figure | (6,095)Free cash flow, Q3 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$6.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001104659-26-059416. Derived: 9-month figure less the 6-month figure.Capital expenditure: $11.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-12, accession 0001104659-26-059416. Derived: 9-month figure less the 6-month figure.Report this figure | (6,247)Free cash flow, Q4 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$6.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-08-28, accession 0001420720-26-000020. Derived: 12-month figure less the 9-month figure.Capital expenditure: $19.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-08-28, accession 0001420720-26-000020. Derived: 12-month figure less the 9-month figure.Report this figure |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY20222022-06-30 | FY20232023-06-30 | FY20242024-06-30 | FY20252025-06-30 | FY20262026-06-30 | Shape over the periods |
|---|---|---|---|---|---|---|---|
| Revenue | $m | 1.9Revenue, FY2022, twelve months to 2022-06-30$1.9m. XBRL concept us-gaap:Revenues. 10-K filed 2023-09-27, accession 0001420720-23-000045.Report this figure | 0.0Revenue, FY2023, twelve months to 2023-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K/A filed 2024-09-24, accession 0001420720-24-000041.Report this figure | 0.2Revenue, FY2024, twelve months to 2024-06-30$225.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-09-05, accession 0001558370-25-011888.Report this figure | 0.4Revenue, FY2025, twelve months to 2025-06-30$400.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-28, accession 0001420720-26-000020.Report this figure | 0.1Revenue, FY2026, twelve months to 2026-06-30$100.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-28, accession 0001420720-26-000020.Report this figure | |
| Gross margin | % | 115.0%Gross margin, FY2022, twelve months to 2022-06-30. gross profit / revenueGross profit: $2.2m. XBRL concept us-gaap:GrossProfit. 10-K filed 2022-10-11, accession 0001420720-22-000064.Revenue: $1.9m. XBRL concept us-gaap:Revenues. 10-K filed 2023-09-27, accession 0001420720-23-000045.Report this figure | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | |
| Operating margin | % | (1576.3%)Operating margin, FY2022, twelve months to 2022-06-30. operating income / revenueOperating income: −$29.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-09-27, accession 0001420720-23-000045.Revenue: $1.9m. XBRL concept us-gaap:Revenues. 10-K filed 2023-09-27, accession 0001420720-23-000045.Report this figure | not reported (Revenue of zero not reported) | (7392.9%)Operating margin, FY2024, twelve months to 2024-06-30. operating income / revenueOperating income: −$16.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-09-05, accession 0001558370-25-011888.Revenue: $225.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-09-05, accession 0001558370-25-011888.Report this figure | (4650.5%)Operating margin, FY2025, twelve months to 2025-06-30. operating income / revenueOperating income: −$18.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-08-28, accession 0001420720-26-000020.Revenue: $400.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-28, accession 0001420720-26-000020.Report this figure | (35141.0%)Operating margin, FY2026, twelve months to 2026-06-30. operating income / revenueOperating income: −$35.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-08-28, accession 0001420720-26-000020.Revenue: $100.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-28, accession 0001420720-26-000020.Report this figure | |
| Net margin | % | (2670.0%)Net margin, FY2022, twelve months to 2022-06-30. net income / revenueNet income: −$50.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2022-10-11, accession 0001420720-22-000064.Revenue: $1.9m. XBRL concept us-gaap:Revenues. 10-K filed 2023-09-27, accession 0001420720-23-000045.Report this figure | not reported (Revenue of zero not reported) | (11069.8%)Net margin, FY2024, twelve months to 2024-06-30. net income / revenueNet income: −$24.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-09-05, accession 0001558370-25-011888.Revenue: $225.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-09-05, accession 0001558370-25-011888.Report this figure | (4594.3%)Net margin, FY2025, twelve months to 2025-06-30. net income / revenueNet income: −$18.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-08-28, accession 0001420720-26-000020.Revenue: $400.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-28, accession 0001420720-26-000020.Report this figure | (33044.0%)Net margin, FY2026, twelve months to 2026-06-30. net income / revenueNet income: −$33.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-08-28, accession 0001420720-26-000020.Revenue: $100.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-28, accession 0001420720-26-000020.Report this figure | |
| Diluted EPS | $ per share | (5.78)Diluted EPS, FY2022, twelve months to 2022-06-30−$5.78 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-09-27, accession 0001420720-23-000045.Report this figure | (106.19)Diluted EPS, FY2023, twelve months to 2023-06-30−$106.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K/A filed 2024-09-24, accession 0001420720-24-000041.Report this figure | (6.50)Diluted EPS, FY2024, twelve months to 2024-06-30−$6.50 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-09-05, accession 0001558370-25-011888.Report this figure | (1.75)Diluted EPS, FY2025, twelve months to 2025-06-30−$1.75 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-08-28, accession 0001420720-26-000020.Report this figure | (0.32)Diluted EPS, FY2026, twelve months to 2026-06-30−$0.32 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-08-28, accession 0001420720-26-000020.Report this figure | |
| Free cash flow | $m | (44.8)Free cash flow, FY2022, twelve months to 2022-06-30. operating cash flow − capital expenditureOperating cash flow: −$37.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-09-27, accession 0001420720-23-000045.Capital expenditure: $7.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-09-27, accession 0001420720-23-000045.Report this figure | (36.2)Free cash flow, FY2023, twelve months to 2023-06-30. operating cash flow − capital expenditureOperating cash flow: −$30.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K/A filed 2024-09-24, accession 0001420720-24-000041.Capital expenditure: $5.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K/A filed 2024-09-24, accession 0001420720-24-000041.Report this figure | (18.8)Free cash flow, FY2024, twelve months to 2024-06-30. operating cash flow − capital expenditureOperating cash flow: −$18.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-09-05, accession 0001558370-25-011888.Capital expenditure: $210.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-09-05, accession 0001558370-25-011888.Report this figure | (15.3)Free cash flow, FY2025, twelve months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$15.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-08-28, accession 0001420720-26-000020.Capital expenditure: $16.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-08-28, accession 0001420720-26-000020.Report this figure | (23.8)Free cash flow, FY2026, twelve months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$23.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-08-28, accession 0001420720-26-000020.Capital expenditure: $578.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-08-28, accession 0001420720-26-000020.Report this figure |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.
No open-market purchases or sales by insiders are in coverage for this company.
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 2026-06-30 | $7.0m | 4,007,881 | Added+900,681 | |
| Cormorant Asset Management, LP | 2026-06-30 | $6.2m | 3,570,000 | New+3,570,000 | |
| SILVERARC CAPITAL MANAGEMENT, LLC | 2026-06-30 | $6.2m | 3,520,490 | Added+3,294,490 | |
| Vestal Point Capital, LP | 2026-06-30 | $4.5m | 2,600,000 | New+2,600,000 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 2026-06-30 | $3.7m | 2,098,151 | Added+1,009,852 | |
| Frazier Life Sciences Management, L.P. | 2026-06-30 | $3.4m | 1,953,467 | Unchanged | |
| Ensign Peak Advisors, Inc | 2026-06-30 | $3.2m | 1,832,457 | New+1,832,457 | |
| Woodline Partners LP | 2026-06-30 | $3.1m | 1,776,547 | New+1,776,547 | |
| MILLENNIUM MANAGEMENT LLC | 2026-06-30 | $2.9m | 1,651,473 | Added+101,623 | |
| CITADEL ADVISORS LLC | 2026-06-30 | $2.4m | 1,384,029 | Added+427,600 |
Recent filings
All 882 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-1920:16 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001420720-26-000032 |
| 2026-10-1312:25 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001420720-26-000030 |
| 2026-09-1420:16 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001420720-26-000028 |
| 2026-09-0420:05 ET | DEF 14A | Proxy statementPeriod 2026-09-04 | 0001420720-26-000022 |
| 2026-08-2812:32 ET | 10-K | Annual reportPeriod 2026-06-30 | 0001420720-26-000020 |
| 2026-08-2812:30 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001420720-26-000019 |
| 2026-08-0411:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001420720-26-000014 |
| 2026-07-1720:08 ET | 8-K | 5.08 Item not in the standard list; 8.01 Other events; 9.01 Financial statements and exhibits | 0001420720-26-000012 |
| 2026-07-0111:33 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001420720-26-000010 |
| 2026-05-1220:18 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001104659-26-059416 |
Latest annual report
Form 10-K for the fiscal year ended Jun 30, 2026Filed Aug 28, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Q1 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter
About the filer
- CIK
- 1420720
- Tickers
- IBIO
- Exchange
- Nasdaq
- SIC code
- 2834 Pharmaceutical Preparations
- Sector
- Healthcare
- Fiscal year ends
- Jun 30
- Incorporated in
- DE
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Former names
- iBio, Inc. (to 2026-10-19); iBioPharma, Inc. (to 2009-08-14); InB:Biotechnologies, Inc. (to 2008-07-17)
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. Listed shows no prices and gives no investment advice.